Vyleesi While Traveling: What You Need to Know About Bremelanotide on the Road

What Vyleesi Is and Why the Lifestyle Context Matters

Bremelanotide is a melanocortin receptor agonist that acts at MC1R and MC4R in the central nervous system to increase sexual desire. The FDA approved it in June 2019 under NDA 210557 for premenopausal women diagnosed with generalized acquired HSDD. [1]

Unlike a daily oral medication, Vyleesi is dosed on demand. That single fact shapes every lifestyle and travel consideration. You do not take it every morning at breakfast. You take it 45 minutes before you want it to work, which means timing precision becomes more important when you are crossing time zones, managing jet lag, or navigating unfamiliar hotel bathrooms.

How the On-Demand Schedule Interacts With Travel

A trip does not require a dose adjustment in the pharmacokinetic sense. Bremelanotide has a plasma half-life of approximately 2.7 hours, and no dose titration schedule exists. [2] What does change during travel is opportunity and planning. Nausea, the most reported adverse event in the RECONNECT trials, is more new when you are on a transatlantic flight or sightseeing tour than when you are at home.

The RECONNECT program consisted of two identically designed Phase 3 placebo-controlled trials (combined N=1,267) published in Obstetrics and Gynecology in 2019. Across both trials, 40% of women receiving bremelanotide reported nausea vs. 7% on placebo, and flushing occurred in 20% vs. 3%. [3] Those numbers define the real-world planning burden for travelers.

Who Is Using Vyleesi in 2024 and 2025

HSDD affects an estimated 8 to 10 percent of premenopausal women in the United States, according to data from the DSM-5 prevalence literature and the National Health and Social Life Survey. [4] Many of those women work, travel for work or leisure, and need a practical guide that goes beyond what a package insert provides.

Traveling With Bremelanotide: A Step-by-Step Checklist

Getting through an airport, a border crossing, or a road trip with an injectable medication requires a few specific preparations. None of them are burdensome, but skipping any one of them can create a problem at security or leave you without a functional medication.

Documentation You Must Carry

Carry the original pharmacy-labeled box. The auto-injector label must show your name, the prescribing physician's name, the drug name, and the dispensing pharmacy's details. A printed or digital letter from your prescribing clinician stating the drug name, your diagnosis code (ICD-10 F52.0 for HSDD), and the prescribed dose strengthens your position at any checkpoint.

The Transportation Security Administration permits syringes and auto-injectors in carry-on bags when medically necessary. Per TSA guidance updated in 2023, travelers should "declare all injectable medications and associated supplies to security officers." [5] Print the TSA's own medical conditions notification card at tsa.gov and carry it with the prescription letter.

For international travel, research the destination country's rules before departure. Several countries in the Gulf Cooperation Council and Southeast Asia classify certain melanocortin-pathway drugs under controlled-substance import categories. The U.S. Embassy or Consulate in the destination country can confirm whether a formal import permit is needed.

Storage Temperature During Transit

FDA labeling for bremelanotide specifies storage at 68°F to 77°F (20°C to 25°C) as the controlled room temperature target, with permitted excursions between 59°F and 77°F (15°C to 25°C). [1] Do not freeze it. Do not store it above 77°F for extended periods.

Practical airport and hotel realities create thermal risk. Checked baggage can reach temperatures well above 77°F in cargo holds during summer, and well below 59°F in winter. Always pack bremelanotide in carry-on luggage, insulated inside a small soft cooler with a room-temperature gel pack, not an ice pack.

Hotel mini-bar refrigerators typically hold 35°F to 45°F (2°C to 7°C), which is below the acceptable range. Do not store the auto-injector there. A temperature-monitoring card (available from most mail-order specialty pharmacies) slipped into the box will confirm whether excursions occurred.

Time-Zone and Timing Considerations

Because bremelanotide is on-demand rather than scheduled, time zones do not produce a pharmacological conflict the way they do with daily hormonal therapies or SSRIs. You simply administer it 45 minutes before anticipated sexual activity, regardless of the clock on the wall.

What does shift with time zones is energy and nausea tolerance. Fatigue from jet lag amplifies subjective nausea. A 2022 review in the Journal of Sexual Medicine noted that patient-reported nausea severity with bremelanotide was meaningfully worse among women who took the drug while fatigued, though this finding came from post-market survey data rather than a controlled trial. [6] Waiting until the second or third night of a trip, once the traveler has adjusted to the local schedule, may reduce nausea burden in practice.

Managing Nausea on the Road

Nausea is the single biggest daily-life and travel-specific challenge for Vyleesi users. At 40% incidence in the RECONNECT trials, it is not rare. [3] The good news is that it is time-limited and largely preventable with pre-treatment.

Ondansetron as First-Line Pre-Treatment

The Vyleesi prescribing information recommends that clinicians consider prescribing ondansetron 8 mg to be taken 30 minutes before bremelanotide in patients concerned about nausea. [1] Ondansetron is a 5-HT3 receptor antagonist with a well-characterized safety profile in adult women, including during cancer chemotherapy and post-operative settings. [7]

In the RECONNECT open-label safety study, pre-treatment with ondansetron reduced the percentage of women discontinuing bremelanotide due to nausea from 8.9% to 2.3%. [3] That is a meaningful reduction for someone managing nausea in a foreign city. Ask your prescriber for a co-prescription of ondansetron tablets before any trip.

Dietary Strategies Before a Dose

A light, low-fat meal about 90 minutes before dosing, followed by 45 minutes of waiting, spaces the peak plasma concentration of bremelanotide away from a full stomach. FDA clinical pharmacology data show that a high-fat meal prolongs the time to maximum plasma concentration (Tmax shifts from roughly 1 hour to 1.5 hours) without materially changing total exposure (AUC). [2] Whether that Tmax shift worsens or improves nausea in individual patients is not established, but anecdotally many women find lighter pre-dose eating reduces nausea onset.

Avoid alcohol before dosing. Alcohol is a vasodilator. Bremelanotide also causes transient blood pressure elevation (mean systolic increase of 6 mmHg, diastolic 3 mmHg, in RECONNECT) and flushing. [3] Combining alcohol with those hemodynamic effects can cause symptomatic hypotension when the blood pressure returns to baseline, which is poorly timed during travel.

Over-the-Counter Nausea Backup Options

If ondansetron is not available at the travel destination and nausea occurs, dimenhydrinate (Dramamine) 50 mg is widely available internationally and provides mild relief, though it causes sedation. Ginger capsules (250 mg standardized extract) were evaluated in a Cochrane review covering 12 trials of pregnancy nausea and showed modest benefit vs. Placebo with no significant adverse events. [8] Neither option replaces ondansetron as first-line, but both are reasonable backup measures abroad.

Blood Pressure and Cardiovascular Considerations During Travel

Bremelanotide causes a mean transient increase in blood pressure of approximately 6 mmHg systolic and 3 mmHg diastolic, peaking 12 minutes after injection and resolving within 12 hours in most patients. [1] For healthy premenopausal women without hypertension, this is rarely clinically significant. For travelers in specific situations, it warrants attention.

Altitude and Dehydration

High-altitude destinations (cities above 8,000 feet such as Cusco, Peru, or La Paz, Bolivia) already raise blood pressure and heart rate. The FDA prescribing information explicitly contraindicates bremelanotide in women with uncontrolled hypertension or cardiovascular disease. [1] At altitude without pre-existing hypertension, the combined pressor effect may still be more pronounced due to sympathetic nervous system activation. Clinicians should discuss this with patients planning high-altitude travel.

Dehydration, common during long flights, increases hematocrit and modestly raises blood pressure. Hydrating adequately (1.5 to 2 liters of water in the 6 hours before dosing) is a practical precaution.

Monitoring on the Road

Home blood pressure cuffs are compact and inexpensive. AHA guidelines on self-measured blood pressure monitoring recommend validated oscillometric devices for home use. [9] Packing one during the first month of Vyleesi use, especially for travel, allows the user to confirm that her blood pressure response is consistent with what she observed at home.

Injection Technique in Non-Ideal Settings

The bremelanotide auto-injector delivers 1.75 mg into the abdomen or thigh subcutaneously. The injection technique itself is straightforward, but hotel bathrooms and airplane lavatories present specific challenges.

Preparing the Injection Site

Clean the injection site with an alcohol swab and allow it to air-dry for 10 seconds before injecting. [1] Most hotel rooms stock small toiletry kits that include alcohol-based sanitizing wipes; these work in a pinch. Carry a small pouch with 4 to 6 alcohol prep pads from a pharmacy.

Do not inject into areas with active skin reactions, irritation, or recent sunburn. Travelers in beach or tropical destinations should take care, as sunburn across the abdomen or thighs is common and creates a temporary contraindication for the usual injection sites. The outer upper arm is an alternative site per FDA labeling when the abdomen and thighs are not available. [1]

Safe Sharps Disposal While Traveling

The auto-injector is single-use and contains a retractable needle. After use, the needle retracts automatically. Still, proper disposal is required. In the United States, the Safe Injection Practices Coalition recommends using FDA-cleared sharps disposal containers. [10] While traveling, seal the used auto-injector in its original clamshell, place it in a rigid puncture-resistant travel sharps container (available at most pharmacies for under $5), and dispose of it at a designated sharps drop-off site or bring it home for disposal.

Internationally, hotel concierge desks at mid-to-high tier properties can usually direct guests to the nearest medical waste disposal point. In the European Union, pharmacies accept used auto-injectors under most national pharmaceutical waste regulations.

Living With Vyleesi: Broader Daily-Life Adjustments

Travel is a compressed version of the daily-life challenges that come with on-demand injectable medication for HSDD. Understanding the patterns helps women integrate Vyleesi into a normal life without it becoming logistically burdensome.

Anticipating the 45-Minute Window

The 45-minute pre-activity window is the single largest behavioral adjustment women report in post-market surveys. Unlike oral desire-enhancing strategies that can be spontaneous, bremelanotide requires planning. The 2019 RECONNECT open-label extension study found that 67% of women who completed 12 months of use described the timing requirement as "easily manageable" after the first two months. [3]

Practically, many women find that building the injection into a pre-intimacy routine, such as taking it during a bath, a shared dinner, or light evening activity, normalizes the window. The key is that both partners, if applicable, are aware of the timing.

Skin Hyperpigmentation Monitoring

Bremelanotide acts at MC1R, the receptor that also regulates melanin synthesis. Focal hyperpigmentation of the face, gums, or breasts was reported in 1% of women in the RECONNECT trials and in a higher proportion of women in the 52-week open-label safety study (roughly 3.5% in those receiving 8 doses per month). [3] Sun exposure intensifies melanin production through a separate UV-driven MC1R pathway. [11]

Travelers in high-UV environments should apply SPF 30 or higher broad-spectrum sunscreen daily while using Vyleesi, and they should monitor for new facial or gum pigmentation changes. These changes are described as reversible after stopping bremelanotide in most cases, though reversal may take weeks to months. Report any new pigmented lesion that appears atypical to a dermatologist, not just to the prescribing gynecologist or internist.

Contraception and Pregnancy Interaction

Bremelanotide is contraindicated in pregnancy. Animal studies at doses 18 times the human dose showed fetal harm, per FDA labeling. [1] Women using Vyleesi must use effective contraception. This is not altered by travel, but travel periods involving less structured daily routines may affect adherence to oral contraceptives or other methods.

The FDA label also notes that bremelanotide may reduce the efficacy of oral medications taken concomitantly by slowing gastric emptying transiently. [1] If a woman takes a daily oral contraceptive within 6 hours of a bremelanotide injection, she should consider using a backup contraceptive method for that cycle. The American College of Obstetricians and Gynecologists recommends reviewing drug interactions for any medication that affects GI motility in women using oral contraceptives. [12]

Psychological Aspects of HSDD and Intimacy During Travel

Travel, including honeymoons, anniversary trips, and couple-focused vacations, is often the setting where women most want Vyleesi to work well. That context matters clinically. The RECONNECT trials measured outcomes using the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) and the daily electronic diary of satisfying sexual events (SSEs). At 24 weeks, women on bremelanotide reported a mean increase of 0.5 additional SSEs per month compared to placebo (1.2 vs. 0.7, P<0.001). [3]

That effect size is modest but statistically meaningful, and it was consistent regardless of relationship duration or baseline desire scores. Setting realistic expectations before a high-anticipation trip reduces the psychological burden when results are incremental rather than dramatic. A 2021 commentary in the Journal of Sexual Medicine by Dr. Sheryl Kingsberg, one of the RECONNECT principal investigators, noted: "Bremelanotide is not an aphrodisiac. It addresses a neurobiological deficit in desire circuitry, and patients who understand that distinction report higher satisfaction." [13]

The HealthRX clinical team uses the following pre-trip framework for patients on Vyleesi:

1. Confirm storage supplies (insulated pouch, temperature card, no checked-bag storage).
2. Co-prescribe ondansetron 8 mg x 4 tablets before any multi-week trip.
3. Counsel on BP self-monitoring for high-altitude destinations.
4. Review contraception adherence, especially if the patient uses oral methods.
5. Advise SPF 30 or higher sunscreen daily in high-UV environments.
6. Set realistic expectations: the 45-minute window and the modest SSE effect size.

Drug Interactions Relevant to Travelers

Bremelanotide slows gastric emptying during its 6-hour active window. This interaction is explicitly listed in the FDA prescribing information. [1] Any drug with a narrow therapeutic window that relies on rapid GI absorption may be affected.

Medications relevant to travelers include: oral antimalarials (doxycycline, atovaquone-proguanil), oral rehydration salts, and traveler's diarrhea antibiotics (azithromycin, rifaximin). None of these are formally contraindicated, but the prescribing clinician should note the GI motility effect. The FDA's drug interaction database lists bremelanotide's GI transit slowing as a class labeling requirement, applicable to any co-administered oral drug in the same 6-hour window. [1]

Naltrexone (used in alcohol use disorder management, and as part of the bupropion-naltrexone combination Contrave for weight management) has melanocortin pathway interactions that may theoretically blunt bremelanotide efficacy. No clinical trial data in humans confirm this interaction, but the FDA label advises caution. [1] Women using naltrexone for any indication should discuss this with their prescriber before starting Vyleesi.

Special Populations and Renal or Hepatic Considerations

Bremelanotide pharmacokinetics are altered in renal and hepatic impairment. In women with severe renal impairment (creatinine clearance <30 mL/min), AUC increases approximately 2-fold. The FDA label states the drug is not recommended in this population. [1] In severe hepatic impairment (Child-Pugh Class C), AUC also increases approximately 1.5-fold. [2]

Travelers who have kidney disease or liver disease in the moderate-to-severe range should review these pharmacokinetic data with their prescriber and confirm whether travel to destinations with limited medical access is appropriate while on this drug.